473 related articles for article (PubMed ID: 26458953)
1. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
[TBL] [Abstract][Full Text] [Related]
2. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
[TBL] [Abstract][Full Text] [Related]
3. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.
Basilico C; Pennacchietti S; Vigna E; Chiriaco C; Arena S; Bardelli A; Valdembri D; Serini G; Michieli P
Clin Cancer Res; 2013 May; 19(9):2381-92. PubMed ID: 23532890
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
Katayama R; Aoyama A; Yamori T; Qi J; Oh-hara T; Song Y; Engelman JA; Fujita N
Cancer Res; 2013 May; 73(10):3087-96. PubMed ID: 23598276
[TBL] [Abstract][Full Text] [Related]
5. Tivantinib: critical review with a focus on hepatocellular carcinoma.
Rota Caremoli E; Labianca R
Expert Opin Investig Drugs; 2014 Nov; 23(11):1563-74. PubMed ID: 25307444
[TBL] [Abstract][Full Text] [Related]
6. Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.
Lu S; Török HP; Gallmeier E; Kolligs FT; Rizzani A; Arena S; Göke B; Gerbes AL; De Toni EN
Oncotarget; 2015 Sep; 6(26):22167-78. PubMed ID: 26259250
[TBL] [Abstract][Full Text] [Related]
7. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.
Calles A; Kwiatkowski N; Cammarata BK; Ercan D; Gray NS; Jänne PA
Mol Oncol; 2015 Jan; 9(1):260-9. PubMed ID: 25226813
[TBL] [Abstract][Full Text] [Related]
8. MIL-1, a novel antitumor agent derived from natural product millepachine, acts as tubulin polymerization inhibitor for the treatment of hepatocellular carcinoma.
Yan J; Zhuang Q; Li Z; Xiong Y; He M; Kang C; Zhang Q; Han L; Liang E; Liu H; Ke P; Huang X
Eur J Pharmacol; 2021 May; 898():173975. PubMed ID: 33647258
[TBL] [Abstract][Full Text] [Related]
9. Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity
Rebouissou S; La Bella T; Rekik S; Imbeaud S; Calatayud AL; Rohr-Udilova N; Martin Y; Couchy G; Bioulac-Sage P; Grasl-Kraupp B; de Koning L; Ganne-Carrié N; Nault JC; Ziol M; Zucman-Rossi J
Clin Cancer Res; 2017 Aug; 23(15):4364-4375. PubMed ID: 28246274
[No Abstract] [Full Text] [Related]
10. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway.
Mao J; Wang D; Wang Z; Tian W; Li X; Duan J; Wang Y; Yang H; You L; Cheng Y; Bian J; Chen Z; Yang Y
Cancer Lett; 2016 Sep; 380(1):134-43. PubMed ID: 27349166
[TBL] [Abstract][Full Text] [Related]
11. Tivantinib in hepatocellular carcinoma.
Trojan J; Zeuzem S
Expert Opin Investig Drugs; 2013 Jan; 22(1):141-7. PubMed ID: 23167786
[TBL] [Abstract][Full Text] [Related]
12. Tivantinib Decreases Hepatocyte Growth Factor-Induced BCRP Expression in Hepatocellular Carcinoma HepG2 Cells.
Kobayashi K; Higai K; Mukozu T; Matsui D; Amanuma M; Yoshimine N; Ogino Y; Matsui T; Wakui N; Shinohara M; Momiyama K; Daido Y; Nagai H; Igarashi Y
Biol Pharm Bull; 2020; 43(9):1421-1425. PubMed ID: 32879217
[TBL] [Abstract][Full Text] [Related]
13. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway.
Yuan S; Gong Y; Chen R; Du J; Zhang H; Chen T
Biomed Pharmacother; 2020 Dec; 132():110867. PubMed ID: 33075668
[TBL] [Abstract][Full Text] [Related]
14. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
[TBL] [Abstract][Full Text] [Related]
15. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
Zhao S; Wu W; Jiang H; Ma L; Pan C; Jin C; Mo J; Wang L; Wang K
Front Immunol; 2021; 12():731527. PubMed ID: 34804015
[TBL] [Abstract][Full Text] [Related]
16. Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.
Wei K; Li M; Zöller M; Wang M; Mehrabi A; Hoffmann K
Cell Death Dis; 2019 Mar; 10(3):231. PubMed ID: 30850583
[TBL] [Abstract][Full Text] [Related]
17. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
[TBL] [Abstract][Full Text] [Related]
18. Tivantinib (ARQ197) in hepatocellular carcinoma.
Porta C; Giglione P; Ferrari A; Reversi F; Liguigli W; Imarisio I; Ganini C
Expert Rev Anticancer Ther; 2015 Jun; 15(6):615-22. PubMed ID: 26035719
[TBL] [Abstract][Full Text] [Related]
19. Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma.
Xi WH; Yang LY; Cao ZY; Qian Y
Biochem Biophys Res Commun; 2015 Feb; 457(4):723-9. PubMed ID: 25623532
[TBL] [Abstract][Full Text] [Related]
20. A Novel Microtubule-Disrupting Agent Induces Endoplasmic Reticular Stress-Mediated Cell Death in Human Hepatocellular Carcinoma Cells.
Ho CT; Chang YJ; Yang LX; Wei PL; Liu TZ; Liu JJ
PLoS One; 2015; 10(9):e0136340. PubMed ID: 26355599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
